From: The high comorbidity burden of the hepatitis C virus infected population in the United States
Conditions associated with treatment | |
---|---|
Conditions associated with Interferon alfa or Ribavirin use [2] (see Table 3; denoted by A) | Interferon only: neutropenia, thrombocytopenia, depression, hypothyroidism and hyperthyroidism, irritability, concentration and memory disturbances, visual disturbances, muscle aches, headaches, nausea and vomiting, low-grade fever, weight loss, insomnia, hearing loss and tinnitus, interstitial fibrosis and hair thinning Both Interferon and Ribavirin: skin irritation, fatigue Ribavirin only: hemolytic anemia, birth defects and gout |
Concurrent disease for which therapy is contraindicated [2] (See Table 3; denoted by B) | major uncontrolled depressive illness; solid organ transplant (renal, heart, or lung); autoimmune hepatitis or other autoimmune condition known to be exacerbated by peginterferon and ribavirin, untreated thyroid disease; severe concurrent medical disease such as severe hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes and chronic obstructive pulmonary disease |
Conditions associated with disease | |
Symptoms of HCV disease [11] (see Table 3; denoted by C) | fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain and jaundice |
Extrahepatic manifestations associated with HCV infection [12] (see Table 3; denoted by D) | rheumatoid symptoms, keratoconjunctivitis sicca, lichen planus, glomerulonephritis, lymphoma, porphyria cutanea tarda, psychological disorders and essential mixed cryoglobulinemia |
Conditions associated with disease progression [2, 13] (see Table 3; denoted by E) | alcohol use, HIV, HBV and obesity essential hypertension [12] (evidence of reducing HCV disease progression) |